poisar

Stocks · News reference

Avalyn Pharma Reports Third Quarter 2026 Financial Results and Business Highlights

Fiscal.ai

Avalyn Pharma announced its financial results for the third quarter ended September 30, 2026, and provided updates on its clinical pipeline, including the initiation of a Phase 1 study for AP03.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. SEC EDGARSEC EDGAR

    8-K filing — Avalyn Pharma Inc. (AVLN)

    Filed: 2026-11-12 AccNo: 0001193125-26-457053 Size: 309 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits